Mayer Davidson to Drug Therapy, Combination
This is a "connection" page, showing publications Mayer Davidson has written about Drug Therapy, Combination.
Connection Strength
0.580
-
Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study. J Diabetes. 2020 Jan; 12(1):91-94.
Score: 0.160
-
Effect of a nurse-directed diabetes disease management program on urgent care/emergency room visits and hospitalizations in a minority population. Diabetes Care. 2007 Feb; 30(2):224-7.
Score: 0.066
-
Exenatide. Nat Rev Drug Discov. 2005 Sep; 4(9):713-4.
Score: 0.060
-
Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: a systematic evaluation of triple oral therapy in a minority population. Diabetes Care. 2004 Jul; 27(7):1741-2.
Score: 0.056
-
Triple therapy: definitions, application, and treating to target. Diabetes Care. 2004 Jul; 27(7):1834-5.
Score: 0.056
-
Twice-Daily NPH or mixture insulins versus triple therapy: apples versus oranges: response to Poulsen et al. Diabetes Care. 2004 Jul; 27(7):1846; author reply 1847-8.
Score: 0.056
-
Established therapies for diabetes mellitus. Curr Med Res Opin. 2002; 18 Suppl 1:s13-21.
Score: 0.047
-
An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997 Jan; 102(1):99-110.
Score: 0.033
-
Rational use of sulfonylureas. Postgrad Med. 1992 Aug; 92(2):69-70, 73-6, 79-85.
Score: 0.024
-
Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med. 1991 Jul 01; 115(1):45-53.
Score: 0.023